Trial · NCT02694978
Results by group28
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 28
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Participants With Treatment-Emergent (TE) Moderate To Severe Hypersensitivity Reactions (Rxns), Including Anaphylaxis, Or Moderate To Severe Hypotension | Ferumoxytol | Moderate hypersensitivity reaction | 3 | Participants | |
| Participants With Treatment-Emergent (TE) Moderate To Severe Hypersensitivity Reactions (Rxns), Including Anaphylaxis, Or Moderate To Severe Hypotension | Ferric Carboxymaltose (FCM) | Moderate hypersensitivity reaction | 6 | Participants | |
| Participants With Treatment-Emergent (TE) Moderate To Severe Hypersensitivity Reactions (Rxns), Including Anaphylaxis, Or Moderate To Severe Hypotension | Ferumoxytol | Severe hypersensitivity reaction | 1 | Participants | |
| Participants With Treatment-Emergent (TE) Moderate To Severe Hypersensitivity Reactions (Rxns), Including Anaphylaxis, Or Moderate To Severe Hypotension | Ferric Carboxymaltose (FCM) | Severe hypersensitivity reaction | 0 | Participants | |
| Participants With Treatment-Emergent (TE) Moderate To Severe Hypersensitivity Reactions (Rxns), Including Anaphylaxis, Or Moderate To Severe Hypotension | Ferumoxytol | Anaphylaxis | 0 | Participants | |
| Participants With Treatment-Emergent (TE) Moderate To Severe Hypersensitivity Reactions (Rxns), Including Anaphylaxis, Or Moderate To Severe Hypotension | Ferric Carboxymaltose (FCM) | Anaphylaxis | 0 | Participants | |
| Participants With Treatment-Emergent (TE) Moderate To Severe Hypersensitivity Reactions (Rxns), Including Anaphylaxis, Or Moderate To Severe Hypotension | Ferumoxytol | Moderate hypotension | 2 | Participants | |
| Participants With Treatment-Emergent (TE) Moderate To Severe Hypersensitivity Reactions (Rxns), Including Anaphylaxis, Or Moderate To Severe Hypotension | Ferric Carboxymaltose (FCM) | Moderate hypotension | 1 | Participants | |
| Participants With Treatment-Emergent (TE) Moderate To Severe Hypersensitivity Reactions (Rxns), Including Anaphylaxis, Or Moderate To Severe Hypotension | Ferumoxytol | Severe hypotension | 0 | Participants | |
| Participants With Treatment-Emergent (TE) Moderate To Severe Hypersensitivity Reactions (Rxns), Including Anaphylaxis, Or Moderate To Severe Hypotension | Ferric Carboxymaltose (FCM) | Severe hypotension | 0 | Participants | |
| Participants With Treatment-Emergent (TE) Moderate To Severe Hypersensitivity Reactions (Rxns), Including Anaphylaxis, Or Moderate To Severe Hypotension | Ferumoxytol | Any TE moderate to severe hypersensitivity rxn | 6 | Participants | |
| Participants With Treatment-Emergent (TE) Moderate To Severe Hypersensitivity Reactions (Rxns), Including Anaphylaxis, Or Moderate To Severe Hypotension | Ferric Carboxymaltose (FCM) | Any TE moderate to severe hypersensitivity rxn | 7 | Participants | |
| Participants With Moderate To Severe Hypersensitivity Reactions, Including Anaphylaxis, Serious Cardiovascular Events, And Death | Ferumoxytol | Moderate hypersensitivity reaction | 3 | Participants | |
| Participants With Moderate To Severe Hypersensitivity Reactions, Including Anaphylaxis, Serious Cardiovascular Events, And Death | Ferric Carboxymaltose (FCM) | Moderate hypersensitivity reaction | 6 | Participants | |
| Participants With Moderate To Severe Hypersensitivity Reactions, Including Anaphylaxis, Serious Cardiovascular Events, And Death | Ferumoxytol | Severe hypersensitivity reaction | 1 | Participants | |
| Participants With Moderate To Severe Hypersensitivity Reactions, Including Anaphylaxis, Serious Cardiovascular Events, And Death | Ferric Carboxymaltose (FCM) | Severe hypersensitivity reaction | 0 | Participants | |
| Participants With Moderate To Severe Hypersensitivity Reactions, Including Anaphylaxis, Serious Cardiovascular Events, And Death | Ferumoxytol | Anaphylaxis | 0 | Participants | |
| Participants With Moderate To Severe Hypersensitivity Reactions, Including Anaphylaxis, Serious Cardiovascular Events, And Death | Ferric Carboxymaltose (FCM) | Anaphylaxis | 0 | Participants | |
| Participants With Moderate To Severe Hypersensitivity Reactions, Including Anaphylaxis, Serious Cardiovascular Events, And Death | Ferumoxytol | Serious cardiovascular event | 6 | Participants | |
| Participants With Moderate To Severe Hypersensitivity Reactions, Including Anaphylaxis, Serious Cardiovascular Events, And Death | Ferric Carboxymaltose (FCM) | Serious cardiovascular event | 13 | Participants |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT02694978/results